Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Minoru Ikoma

Sachie Morimoto

Koji Watanabe

Shuji Kitamura

Zenichi Ikeda

Hideki Hirose

Takafumi Yukawa

Satoshi Sasaki

Tsuneo Yasuma

Taiji Asami

Nobuyuki Takakura

Tsuyoshi Maekawa

Keiko Kakegawa

Shigemitsu Matsumoto

Minoru Yoshida

Yoshihide Tomata

Atsuko Ochida

Naoki Nishizawa

Toshitake Kobayashi

Yoshihiro Banno

Kenjiro Sato

Jumpei Aida

Hideyuki Igawa

Ayumu Niida

Yoshito Terao

Naoyoshi Noguchi

Kei Masuda

Hideto Fukushi

Ryoma Hara

The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

Macrocyclic compound and use thereof

Heterocyclic compound

The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Aromatic ring compound

Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Minoru Ikoma